For the first time in humans, experiments with the cancer-killing virus have begun
LOS ANGELES (Reuters) – For the first time in history, a modified cancer-testing virus has been tested on a patient, and a new cancer treatment is expected to emerge.
Experts have genetically modified an oncolytic or carcinogenic virus and combined it into a drug called CF33-hNIS, but it is also known simply as vaccine.
CF33HNIS is a modified measles virus that does not cause disease but spreads to cancer cells, increasing its number and even tearing the affected cell. The virus now produces hundreds of thousands of new particles that act as antigens to activate the body’s own immune system and attack surrounding cancer cells. This is how it works in two ways.
Testing them on animals has yielded encouraging results, but so far no human has been tested. Now the City of Hope Cancer Center in Los Angeles and the Australian Immogene Company have announced the first trials on humans.
In the first phase, 100 people will be assessed for the safety of the treatment. However, central scientist Daning Lee said that oncolytic cells can boost the body’s immune system against cancer and are often effective with aminotherapy. He hopes that CF33HNIS will help in the treatment of patients.
All 100 people in the experiment had solid and large cancerous abscesses in their bodies that had undergone the first two standard treatments. All patients will be injected with a low-dose drug directly into the flesh or vein. During this time a team of doctors will examine all the patients.
The human sodium iodide supporter, or HNIS, contained in the drug is a type of protein that will help the body capture the growing number of viruses, destroy cancer cells, and photograph other routines.
